IGF1 and neoplasm: In this regard, Shariat et al. (2003) suggested that blocking IGF-1R would inhibit tumour growth and possibly reverse chemo-resistance [44], indicating the potential importance of the IGF axis in BCa and the need to identify suitable candidate biomarkers for patient selection in this setting.